Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., AUG. 06, 2025 (GLOBE NEWSWIRE) -- MERUS N.V. (NASDAQ: MRUS), AN ONCOLOGY COMPANY DEVELOPING INNOVATIVE, FULL-LENGTH MULTISPECIFIC ANTIBODIES AND ANTIBODY DRUG CONJUGATES (BICLONICS, TRICLONICS AND ADCLONICS), TODAY ANNOUNCED THAT BILL LUNDBERG, M.D., PRESIDENT, CHIEF EXECUTIVE OFFICER OF MERUS, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE ON WEDNESDAY, AUGUST 13, 2025 AT 1:30 P.M. ET.

MERUS TO PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE

- PETOSEMTAMAB IN COMBINATION WITH PEMBROLIZUMAB IN 1L PD-L1+ R/M HNSCC PHASE 2 TRIAL DEMONSTRATES 63% RESPONSE RATE OBSERVED AMONG 43 EVALUABLE PATIENTS AND 79% OVERALL SURVIVAL RATE AT 12-MONTHS

MERUS ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND PROVIDES BUSINESS UPDATE

UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., AUG. 04, 2025 (GLOBE NEWSWIRE) -- MERUS N.V.(NASDAQ: MRUS) (MERUS, THE COMPANY, WE AND OUR), AN ONCOLOGY COMPANY DEVELOPING INNOVATIVE, FULL-LENGTH MULTISPECIFIC ANTIBODIES AND ANTIBODY DRUG CONJUGATES (BICLONICS, TRICLONICSAND ADCLONICS), TODAY ANNOUNCEDTHAT THE COMPANY GRANTED NON-STATUTORY STOCK OPTIONS TO TWO NEW EMPLOYEES AS AN INDUCEMENT AWARD OUTSIDE THE COMPANY'S 2016 INCENTIVE AWARD PLAN (THE PLAN) IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE COMPANY GRANTED STOCK OPTIONS TO PURCHASE UP TO AN AGGREGATE OF 240,000 SHARES OF ITS COMMON STOCK TO TWO NEW EMPLOYEES. THE STOCK OPTIONS WERE GRANTED ON AUGUST 1, 2025. THE GRANT WAS APPROVED BY THE BOARD OF DIRECTORS AND A MAJORITY OF INDEPENDENT DIRECTORS BASED ON THE RECOMMENDATION OF THE COMPENSATION COMMITTEE AND MADE AS A MATERIAL INDUCEMENT TO SUCH EMPLOYEES ENTERING INTO EMPLOYMENT WITH MERUS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE OPTION AWARDS HAVE AN EXERCISE PRICE OF $ 65.56 PER SHARE, THE CLOSING PRICE OF MERUS' COMMON STOCK ON AUGUST 1, 2025. THE OPTIONS HAVE A TEN-YEAR TERM AND VEST OVER FOUR YEARS, WITH 25% OF THE ORIGINAL NUMBER OF SHARES VESTING ON THE FIRST ANNIVERSARY OF THE EMPLOYEE'S NEW HIRE DATE AND THE REMAINDER VESTING IN EQUAL MONTHLY INSTALLMENTS OVER THE FOLLOWING THREE YEARS. THE AWARDS ARE SUBJECT TO THE AWARD HOLDER'S CONTINUOUS SERVICE THROUGH EACH VESTING DATE AND TO THE TERMS AND CONDITIONS OF THE PLAN AND THE STANDARD FORMS OF GRANT AGREEMENTS THEREUNDER.

MERUS N.V. REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NEW YORK--(BUSINESS WIRE)--MERUS GLOBAL INVESTMENTS (MERUS), A MULTI-STRATEGY INVESTMENT PARTNERSHIP, TODAY UNVEILED ITS REFRESHED WEBSITE AND ANNOUNCED A SERIES OF SENIOR PROMOTIONS AND STRATEGIC ADDITIONS ACROSS ITS INVESTMENT AND MANAGEMENT TEAMS. THESE MOVES REFLECT MERUS' CONTINUED COMMITMENT TO ATTRACTING TOP TALENT, FOSTERING INTERNAL GROWTH, AND INVESTING IN LONG-TERM SUCCESS: ADAM DECKER AND RYAN RIZZO HAVE BEEN NAMED CO-MANAGING PARTNERS, LEADING THE FIRM'S TRADING STRATEGY. THEY WI.

MERUS GLOBAL INVESTMENTS STRENGTHENS LEADERSHIP AND EXPANDS TALENT BENCH WITH STRATEGIC HIRES AND KEY PROMOTIONS

UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., JUNE 04, 2025 (GLOBE NEWSWIRE) -- MERUS N.V. (NASDAQ: MRUS) (MERUS, THE COMPANY, WE AND OUR), AN ONCOLOGY COMPANY DEVELOPING INNOVATIVE, FULL-LENGTH MULTISPECIFIC ANTIBODIES AND ANTIBODY DRUG CONJUGATES (BICLONICS, TRICLONICSAND ADCLONICS), TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5,263,158 COMMON SHARES, AT A PUBLIC OFFERING PRICE OF $57.00 PER SHARE (THE OFFER SHARES). MERUS ALSO GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 789,473 COMMON SHARES (THE OPTION SHARES AND TOGETHER WITH THE OFFER SHARES, THE SHARES). THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES AND EXCLUDING THE UNDERWRITERS' OPTION TO PURCHASE THE OPTION SHARES, ARE EXPECTED TO BE APPROXIMATELY $300.0 MILLION. ALL OF THE SHARES IN THE OFFERING ARE TO BE SOLD BY MERUS.

MERUS N.V. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., JUNE 03, 2025 (GLOBE NEWSWIRE) -- MERUS N.V.

MERUS N.V. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., MAY 27, 2025 (GLOBE NEWSWIRE) -- MERUS N.V.

MERUS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

- 63% RESPONSE RATE OBSERVED AMONG 43 EVALUABLE PATIENTS - 79% OVERALL SURVIVAL RATE AT 12-MONTHS; 9 MONTHS MEDIAN PROGRESSION-FREE SURVIVAL - CONFERENCE CALL ON THURSDAY, MAY 22 AT 5:30 P.M. ET UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS.

MERUS' PETOSEMTAMAB WITH PEMBROLIZUMAB INTERIM DATA DEMONSTRATES ROBUST EFFICACY AND DURABILITY IN 1L PD-L1+ R/M HNSCC

UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., MAY 15, 2025 (GLOBE NEWSWIRE) -- MERUS N.V.

MERUS ANNOUNCES THE JOURNAL PUBLICATION OF PETOSEMTAMAB MECHANISM OF ACTION

UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., MAY 08, 2025 (GLOBE NEWSWIRE) -- MERUS N.V.

Merus N.V.

MRUS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Merus N.V.

MRUS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MRUS